Contemporary Accounts in Drug Discovery and Development. Группа авторов

      

      Table of Contents

      1  Cover

      2  Title Page

      3  Copyright Page

      4  Preface

      5  List of Contributors

      6  1 Current Drug Discovery: Great Challenges and Great Opportunity (an Introduction to Contemporary Accounts in Drug Discovery and Development ) References

      7  2 Advanced Computational Modeling Accelerating Small‐Molecule Drug Discovery: A Growing Track Record of Success 2.1 Introduction 2.2 Essential Techniques 2.3 Illustrative Applications 2.4 Conclusion and Future Outlook References

      8  3 Discovery and Development of the Soluble Guanylate Cyclase Stimulator Vericiguat for the Treatment of Chronic Heart Failure 3.1 Introduction 3.2 Soluble Guanylate Cyclase Stimulators as Treatment Option for Heart Failure 3.3 Medicinal Chemistry Program 3.4 Synthesis Routes toward Vericiguat 3.5 Preclinical Studies 3.6 Clinical Studies 3.7 Summary References

      9  4 Finding Cures for Alzheimer's Disease: From γ‐Secretase Inhibitors to γ‐Secretase Modulators and β‐Secretase Inhibitors 4.1 Introduction 4.2 γ‐Secretase Inhibitors Drug Discovery and Development 4.3 γ‐Secretase Modulator Drug Discovery and Development 4.4 Overview of β‐Secretase Inhibitors 4.5 Summary Acknowledgement References

      10  5 Discovery of Novel Antiviral Agents Enabled by Structural Biology, Compact Modules and Phenotypic Screening 5.1 Introduction 5.2 Discovery and Early Development of Novel Core Protein Assembly Modulators for the Treatment of Chronic Hepatitis B Virus Infection 5.3 RG7834: The First‐in‐Class Selective and Orally Bioavailable Small Molecule HBV Expression Inhibitor with a Novel Mode of Action 5.4 Ziresovir: The Discovery of a Highly Potent, Selective and Orally Bioavailable RSV Fusion Protein Inhibitor 5.5 Conclusion References

      11  6 Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors 6.1 Background 6.2 Discovery of Subtype Selective Agonist LY2812223 of the MGLU₂ Receptor 6.3 Discovery of Subtype Selective Agonist LY2794193 OF THE MGLU₃ Receptor 6.4 Structural Basis for Subtype Selectivity 6.5 Divergent Synthesis of 11 and 19 6.6 Clinical Experience with MGLU₂ Selective Agonist 11 (Via its Prodrug 12) 6.7 Conclusion References

      12  7 Discovery of Taselisib (GDC‐0032): An Inhibitor of PI3Kα with Selectivity over PI3Kβ 7.1 Introduction 7.2 Hit to Lead Efforts 7.3 Final Lead Optimization Leading to Discovery of Taselisib: ADME Optimization and Achieving Selective Inhibition of PI3Kα over PI3Kβ 7.4 Preclinical in vivo Pharmacology of Taselisib 7.5 Prediction and Clinical Assessment of Taselisib Human Pharmacokinetics 7.6 Conclusion References

      13  8 Drug Discovery with DNA‐Encoded Library Technology 8.1 Background of DNA‐Encoded Library Technology 8.2 Application of DNA‐Encoded Library Technology in Small Molecule Drug Discovery 8.3 Discovery of Soluble Epoxide Hydrolase Inhibitors Via DNA‐Encoded Library Technology 8.4 Summary References

      14  9 Discovery of HTL26119: Family B GPCR Structure‐Based Drug Design Is Now a Reality